Literature DB >> 25156493

ArhGAP30 promotes p53 acetylation and function in colorectal cancer.

Jilin Wang1, Jin Qian1, Ye Hu2, Xuan Kong2, Haoyan Chen2, Qinghua Shi3, Long Jiang3, Chenming Wu4, Weiping Zou5, Yingxuan Chen2, Jie Xu2, Jing-Yuan Fang2.   

Abstract

Covalent modification adding acetyl groups to the C terminus of the p53 protein has been suggested to be required for its functional activation as a tumour suppressor. However, it remains largely unknown how p53 acetylation is deregulated in colorectal cancer (CRC), which is the third most commonly diagnosed cancer worldwide. Here we show that ArhGAP30, a Rho GTPase-activating protein, is a pivotal regulator for p53 acetylation and functional activation in CRC. ArhGAP30 binds to p53 C-terminal domain and P300, facilitating P300-mediated acetylation of p53 at lysine 382. ArhGAP30 expression is required for p53 activation upon DNA damage stress, and the level of ArhGAP30 correlates with p53 acetylation and functional activation in CRC tissues. Moreover, low level of ArhGAP30 expression associates with poor survival of CRC patients. In summary, ArhGAP30 is required for p53 acetylation and functional activation in CRC, and the expression of ArhGAP30 is a potential prognostic marker for CRC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25156493     DOI: 10.1038/ncomms5735

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  33 in total

1.  PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation.

Authors:  Huanbin Wang; Han Yao; Chushu Li; Lunxi Liang; Yao Zhang; Hubing Shi; Chongzhi Zhou; Yingxuan Chen; Jing-Yuan Fang; Jie Xu
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

Review 2.  Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy.

Authors:  L Liang; J-Y Fang; J Xu
Journal:  Oncogene       Date:  2015-06-15       Impact factor: 9.867

Review 3.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

4.  Transcriptomic Analysis Identified ARHGAP Family as a Novel Biomarker Associated With Tumor-Promoting Immune Infiltration and Nanomechanical Characteristics in Bladder Cancer.

Authors:  Chen Yang; Siqi Wu; Zezhong Mou; Quan Zhou; Zheyu Zhang; Yiling Chen; Yuxi Ou; Xinan Chen; Xiyu Dai; Chenyang Xu; Na Liu; Haowen Jiang
Journal:  Front Cell Dev Biol       Date:  2021-07-07

Review 5.  Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.

Authors:  Guilherme A P de Oliveira; Luciana P Rangel; Danielly C Costa; Jerson L Silva
Journal:  Front Oncol       Date:  2015-04-29       Impact factor: 6.244

6.  Epigenetic reprogramming of melanoma cells by vitamin C treatment.

Authors:  Christopher B Gustafson; Cuixia Yang; Kevin M Dickson; Hongwei Shao; Derek Van Booven; J William Harbour; Zhao-Jun Liu; Gaofeng Wang
Journal:  Clin Epigenetics       Date:  2015-04-29       Impact factor: 6.551

7.  ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells.

Authors:  N Luo; J Guo; L Chen; W Yang; X Qu; Z Cheng
Journal:  Cell Death Dis       Date:  2016-03-24       Impact factor: 8.469

Review 8.  Scaffold Proteins in Gastrointestinal Tumors as a Shortcut to Oncoprotein Activation.

Authors:  Chushu Li; Huanbin Wang; Han Yao; Jing-Yuan Fang; Jie Xu
Journal:  Gastrointest Tumors       Date:  2017-07-12

Review 9.  Genetic and biological hallmarks of colorectal cancer.

Authors:  Jiexi Li; Xingdi Ma; Deepavali Chakravarti; Shabnam Shalapour; Ronald A DePinho
Journal:  Genes Dev       Date:  2021-06       Impact factor: 11.361

10.  Scaffold proteins in cancer.

Authors:  Jie Xu; Jing-Yuan Fang
Journal:  Oncoscience       Date:  2015-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.